Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa

Recruiting in Palo Alto (17 mi)

+4 other locations

Overseen by Evelyn Attia, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: New York State Psychiatric Institute

Trial Summary

What is the purpose of this trial?

Anorexia Nervosa (AN) is a serious illness associated with substantial morbidity and mortality. Weight restoration is a treatment priority, and better treatments are needed.

Research Team

Evelyn Attia, MD

Principal Investigator

New York State Psychiatric Institute

Eligibility Criteria

Inclusion Criteria

Diagnosis of Anorexia Nervosa

Body Mass Index (BMI) between 14.0 and 18.5 kg/m2

Between 18-75 years old

Treatment Details

Interventions

• Olanzapine (Antipsychotic)
• Placebo (Other)

Participant Groups

Group I: Olanzapine Experimental Treatment 1 Intervention

Group receiving olanzapine

Group II: Placebo Placebo Group 1 Intervention

Control group receiving placebo

Who Is Running the Clinical Trial?

New York State Psychiatric Institute

Lead Sponsor

Trials

481

Recruited

154,000+

Dr. Elizabeth B. Ford

New York State Psychiatric Institute

Chief Medical Officer since 2023

MD

Dr. Joshua A. Gordon

New York State Psychiatric Institute

Chief Executive Officer

MD, PhD in Neuroscience

University of Toronto

Collaborator

Trials

739

Recruited

1,125,000+

Allison Brown

University of Toronto

Chief Medical Officer

PhD in Chemical Engineering from the University of Toronto

Michael Sefton

University of Toronto

Chief Executive Officer since 2017

PhD in Chemical Engineering from the University of Toronto and MIT

National Institute of Mental Health (NIMH)

Collaborator

Trials

3,007

Recruited

2,852,000+

Dr. Joshua A. Gordon

National Institute of Mental Health (NIMH)

Chief Executive Officer since 2016

MD, PhD

Dr. Shelli Avenevoli

National Institute of Mental Health (NIMH)

Chief Medical Officer

PhD

Weill Medical College of Cornell University

Collaborator

Trials

1,103

Recruited

1,157,000+

Dr. Robert Min

Weill Medical College of Cornell University

Chief Executive Officer since 2024

MD, MBA

Dr. Adam R. Stracher

Weill Medical College of Cornell University

Chief Medical Officer since 2024

MD

University of Pittsburgh

Collaborator

Trials

1,820

Recruited

16,360,000+

David Apelian

University of Pittsburgh

Chief Executive Officer since 2019

PhD in Molecular Biology from Rutgers University, MD from the University of Medicine and Dentistry of New Jersey, MBA from Quinnipiac University

Pamela D. Garzone

University of Pittsburgh

Chief Medical Officer

PhD in Clinical Science from the University of Pittsburgh

Johns Hopkins University

Collaborator

Trials

2,366

Recruited

15,160,000+

Theodore DeWeese

Johns Hopkins University

Chief Executive Officer since 2023

MD from an unspecified institution

Allen Kachalia

Johns Hopkins University

Chief Medical Officer since 2023

MD from an unspecified institution